The firm currently serves on the Executive Committee, representing any person or entity who purchased Solodyn or its generic equivalent in the United States, District of Columbia, or Puerto Rico from December 2008 to present. Plaintiffs allege Medicis Pharmaceuticals and a number of generic drug manufacturers conspired to monopolize the market for the minocycline hydrochloride-based acne drug Solodyn by illegally preventing an artificial version from going to market.

Main Menu